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Abst ract
Golimumab is a human IgG mo noclo nal ant ibody specific for huma n t umor necrosis fact or alpha (TNF -α). Golimumab has been approved for use in r heumat o logical co ndit io ns; however, it s use in inflammat or y bowel disease (IBD) is st ill in clinical t ria ls. We report a case of an exacer bat ion o f ulcerat ive proct it is aft er st art ing on golimumab for ankylo sing spondylit is ( AS).
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Int roduction:
Golimumab is a human IgG mo noclo nal ant ibody specific for huma n t umor necrosis fact or alpha (TNF-α). Golimumab has been approved for use in r heumat o logical co ndit io ns; however, it s use in inflammat or y bowel disease (IBD) is st ill in clinical t ria ls. We report a case of an exacer bat ion o f ulcerat ive proct it is aft er st art ing on golimumab for ankylo sing s pondylit is ( AS).
Case:
A 25-year-o ld male wit h ulcerat ive proct it is was t reat ed wit h t opica l mesala mine wit h sympt o ms reso lut io n for 14 mont hs. In Januar y 2011, t he pat ient st art ed complaining of r ight hip and lower back pain. An X-ray reveale d jo int space narrowing and r ight sacro iliit is. Blood t est for HLA B27 was posit ive. The pat ient was referr ed to rheumat ologist for furt her management . He was st art ed on g olimumab for t he t reat ment of AS in March 2011.
One mo nt h lat er his jo int and back pain improved markedly w it h golimu mab t reat ment . Three mo nt hs aft er being on go limumab, he present ed wit h hemat ochezia associat ed wit h w at er y diarr hea and weight lo ss. P hys ical examinat io n was unremarkable except for left lower 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 quadrant t ender ness. Co lo noscopy revealed act ive ulcer at ive proct it is confir med by b iopsy. T he dose o f topical mesela mine was incr eased t o t wice a day. T he pat ient 's sympt oms part ially improved aft er one mont h, however, so me sympt o ms persist ed. Go limumab t herap y was st opped and adalimuma b was st art ed as t reat ment fo r int est inal and ext ra -int est inal manifest at ions o f IBD. His sympt o ms improved markedly w it hin a few weeks of go limu mab cessat io n and init iat ion o f adalimumab . Fo llow up flexible sigmo idoscopy revealed reso lut ion of proct it is. His proct it is is current ly in r emissio n, however he st ill has minimal jo int disco mfort .
Discu ssion:
TNF-α, or igina lly known as cachexin, was descr ibed in 1975 and recognized for it s abilit y t o lyse t umors in a var iet y o f in vit ro models (hence t he name "t umor necrosis factor") .
[1] Golimu mab, human mo noclo nal ant ibody t hat binds t o human t umor necrosis fact or alpha (TNF-α). Alt hough TNF-α inhibit ors share same mode o f act ion, t he y show so me t herapeut ic differ ences in t heir effect s on ext ra -art icular organ manifest at ion. [2] [3] [4] We present a case of go limu mab-induced flare up of ulc erat ive proct it is wit h a review o f lit erat ure. Our pat ient had been in r emissio n for almo st 14 mo nt hs and had acut e flare up o f ulc era t ive proct it is (confir med wit h 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 co lonoscopy and biops y) aft er being int roduced on Go limumab t her apy and his sympt o ms re markably improved wit hin few weeks o f swit ching t he t herapy t o adalimu mab. In t he E nglish lit erat ure search t here have bee n tot al of 4 cases ( including our pat ient ) [ Table 1 ] who had parado xica l acut e flare up o f I nflammat or y bowel disease aft er been st art ed on golimu mab. This t ype of paradoxical effect of TNF -α inhibit or has bee n report ed for ext raart icular manifest at ions, [5, 6] however, t he mechanis m of act ion is st ill un clear, alt hough an imbalance of cyt okines and int er feron α in genet ically predisposed individuals has been suggest ed.
[7,8]
Conclusi on:
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